Analysis of the EAP, page-20

Thanks for your write up Left-E, i have also been visiting the Yahoo boards for your commentary.

I am very very confident on these preliminary results due soon..

So just to summarise, the 12 person EAP was specifically for people on deaths door, after all other treatments failed and we still managed 83% success rate. Now we have a trial where patients must be treated with Rem-L within 72hrs of being on Ventilator, so Meso is treating patients earlier on, before they cycle through multiple treatments first and before they reach being classified critical....

So with that in mind, with this new Phase 3 trial, we're allowing Rem-L a better chance of an even better success rate as we're treating patients earlier?

Please correct me if i'm incorrect.